Anemia

Phase I Safety Study Initiated of Recombinant Hemoglobin Treatment

Published in Blood Weekly, June 17th, 1996

Somatogen, Inc., Boulder, Colorado, announced that the company has initiated a Phase I trial of its recombinant hemoglobin (rHb1.1) as an agent for stimulating red blood cell formation (hematopoiesis).

The study will evaluate the safety and hematopoietic activity of repeated low doses of rHb1.1 in approximately 50 patients with anemia resulting from End Stage Renal Disease (ESRD).

The randomized, double-blind, placebo-controlled trial is a dose-ranging study conducted at five sites within the United States. Participants in the trial have been on hemodialysis for six months or more, and have responded to treatment with exogenous erythropoietin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry